GOETTINGEN, Germany--(BUSINESS WIRE)--At today’s meeting, the Supervisory Board of Sartorius AG approved the Executive Board’s recommendation to submit a proposal to the Annual Shareholders’ Meeting on April 7, 2016, to raise dividends to 1.52 euros per preference share (previous year: 1.08 euros) and 1.50 euros per ordinary share (previous year: 1.06 euros). If approved, the total amount disbursed under this proposal would thus rise by 41.5% year over year from 18.2 million euros to 25.8 million euros.
In addition, a resolution to increase share capital by use of retained earnings for carrying out a so-called stock split will also be submitted to the Annual Shareholders’ Meeting in order to encourage trading with Sartorius shares and make them attractive to even broader groups of investors. Under this proposal, every shareholder would receive three additional shares of the same type for every share held, without an additional payment. For this purpose, capital reserves would be converted and share capital would accordingly quadruple to 74,880,000 euros. This share capital increase from retained earnings would not have any impact on the company’s equity. Furthermore, a surplus dividend of 0.01 euro per preference share and a minimum dividend of 0.02 euro per preference share would be established.
Upcoming Financial Dates
|February 26, 2016||Annual press conference|
|April 7, 2016||Annual Shareholders’ Meeting|
|April 21, 2016||Publication of first-quarter figures (January to March 2016)|
This press release contains statements about the future development of the Sartorius Group. The content of these statements cannot be guaranteed as they are based on assumptions and estimates that harbor certain risks and uncertainties. This is a translation of the original German-language press release. Sartorius shall not assume any liability for the correctness of this translation. The original German press release is the legally binding version. Furthermore, Sartorius reserves the right not to be responsible for the topicality, correctness, completeness or quality of the information provided. Liability claims regarding damage caused by the use of any information provided, including any kind of information which is incomplete or incorrect, will therefore be rejected.
A Profile of Sartorius
The Sartorius Group is a leading international pharmaceutical and laboratory equipment provider with two divisions: Bioprocess Solutions and Lab Products & Services. Bioprocess Solutions with its broad product portfolio focusing on single-use solutions helps customers produce biotech medications and vaccines safely and efficiently. Lab Products & Services, with its premium laboratory instruments, consumables and services, concentrates on serving the needs of laboratories performing research and quality assurance at pharma and biopharma companies and on those of academic research institutes. Founded in 1870, the company earned sales revenue of more than 1.1 billion euros in 2015. The Sartorius Group employs around 6,200 people and has manufacturing and sales sites in some 110 countries.